Drug Profile

Vorinostat - Merck & Co

Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Zolinza

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Columbia University; Memorial Sloan-Kettering Cancer Center
Developer Banyu; Bayer; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; H. Lee Moffitt Cancer Center and Research Institute; Indiana University; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Center for Tumor Diseases; Roswell Park Cancer Institute; Stanford University; Takeda; University Hospital Heidelberg; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
Class Antineoplastics; Hydroxamic acids; Small molecules
Mechanism of Action Histone deacetylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cutaneous T-cell lymphoma; Multiple myeloma; Malignant-mesothelioma
New Molecular Entity Yes

Marketed Cutaneous T-cell lymphoma
Phase II Acute myeloid leukaemia; B-cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
Phase I/II Leukaemia; Lymphoma; Solid tumours
No development reported Brain metastases; Colorectal cancer; Glioblastoma; Gliosarcoma; Hodgkin's disease
Discontinued Gynaecological cancer; Malignant-mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sickle cell anaemia

28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours in Unknown (PO, Capsule)
28 Jun 2023 H. Lee Moffitt Cancer Center and Research Institute in collaboration with Merck completes a phase I trial in Gliosarcoma and Glioblastoma (Newly diagnosed, Combination therapy) in USA (PO) (NCT03426891)
15 Jun 2023 Merck Sharp & Dohme in collaboration with University of California terminates a phase II trial in Breast cancer (Combination therapy, Late-stage disease) in USA (PO) due to low accrual (NCT04190056)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com